GANX

Gain Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1819411Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(20.0M)

EPS (Basic, as reported)

$-0.61

Net Margin FY2025

—

ROE FY2025

-108.6%

Total Equity

$19.0M

Shares Out

44M

Business description

Gain Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 0

Fiscal yearFY2020⚑FY2021FY2022FY2023⚑FY2024⚑FY2025

Revenue0000——

Research & development(2)(7)(8)(12)(11)(10)

General & administrative(1)(7)(10)(11)(10)(8)

Total operating expenses(4)(14)(18)(22)(20)(19)

Operating income(3)(14)(18)(22)(20)(19)

Interest expense—0————

Pre-tax income(4)(14)(17)(22)(20)(19)

Income tax expense0000(1)(1)

Net income(4)(14)(18)(22)(20)(20)

EPS — basic($1.33)($1.37)($1.48)($1.71)($0.89)($0.61)

EPS — diluted($1.33)($1.37)($1.48)($1.71)($0.89)($0.61)

Shares outstanding — basic (M)31012132333

Shares outstanding — diluted (M)31012132333

⚑ Weighted-average shares changed ×3.33 between FY2020 and FY2021 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.77 between FY2023 and FY2024 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
⚑ Weighted-average shares changed ×1.43 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.